The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Open accessAbstract
BACKGROUND: Uveal melanoma is a disease that is distinct from cutaneous melanoma, with a low tumor mutational burden and a 1-year overall survival of approximately 50% in patients with metastatic uveal melanoma. Data showing a proven overall survival benefit with a systemic treatment are lacking. Tebentafusp is a bispecific protein consisting of an affinity-enhanced T-cell receptor fused to an anti-CD3 effector that can redirect T cells to target glycoprotein 100-positive cells. METHODS: In this open-label, phase 3 trial, we randomly assigned previously untreated HLA-A*02:01-positive patients with metastatic uveal melanoma in a 2:1 ratio to receive tebentafusp (tebentafusp group) or the investigator's choice of therapy with single-agent pembrolizumab, ipilimumab, or dacarbazine (control group), stratified according to the lactate dehydrogenase level. The primary end point was overall survival. RESULTS: A total of 378 patients were randomly assigned to either the tebentafusp group (252 patients) or the control group (126 patients). Overall survival at 1 year was 73% in the tebentafusp group and 59% in the control group (hazard ratio for death, 0.51; 95% confidence interval [CI], 0.37 to 0.71; P<0.001) in the intention-to-treat population. Progression-free survival was also significantly higher in the tebentafusp group than in the control group (31% vs. 19% at 6 months; hazard ratio for disease progression or death, 0.73; 95% CI, 0.58 to 0.94; P = 0.01). The most common treatment-related adverse events in the tebentafusp group were cytokine-mediated events (due to T-cell activation) and skin-related events (due to glycoprotein 100-positive melanocytes), including rash (83%), pyrexia (76%), and pruritus (69%). These adverse events decreased in incidence and severity after the first three or four doses and infrequently led to discontinuation of the trial treatment (2%). No treatment-related deaths were reported. CONCLUSIONS: Treatment with tebentafusp resulted in longer overall survival than the control therapy among previously untreated patients with metastatic uveal melanoma. (Funded by Immunocore; ClinicalTrials.gov number, NCT03070392; EudraCT number, 2015-003153-18.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, tebentafusp-tebn, a bispecific fusion protein consisting of a soluble TCR specific to gp100 (expressed by melanoma cells) linked to an anti-CD3 single-chain antibody fragment that targets T cells, has been approved for the treatment of metastatic uveal melanoma based on an OS benefit observed in a phase III trial199.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [199]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Tumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230
Wolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214
Self-citationDiscrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Checking the Cox model with cumulative sums of martingale-based residuals
LIN, D. Y., WEI, L. J., & YING, Z. (1993) · Biometrika · doi:10.1093/biomet/80.3.557 · Cited by 1,432
Very Long-Term Prognosis of Patients with Malignant Uveal Melanoma
Kujala, E., Mäkitie, T., & Kivelä, T. (2003) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.03-0538 · Cited by 1,046
Jager, M. J., Shields, C. L., Cebulla, C. M., Abdel‐Rahman, M. H., Grossniklaus, H. E., Stern, M., Carvajal, R. D., Belfort, R. N., Jia, R., Shields, J. A., et al. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0158-0 · Cited by 857
Self-citation
Cited by
Sorted by citations
Items 401–500 of 935
Pham, J. P., Star, P., Ardolino, L., Smith, A. D., & Joshua, A. M. (2022) · Australasian Journal of Dermatology · doi:10.1111/ajd.13866 · Cited by 8
Self-citationLeyvraz, S., Konietschke, F., Peuker, C. A., Schütte, M., Kessler, T., Ochsenreither, S., Ditzhaus, M., Sprünken, E. D., Dörpholz, G., Lamping, M., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.04.004 · Cited by 8
Self-citationCombination strategies to durably suppress HIV-1: Soluble T cell receptors
Wallace, Z., Singh, P., & Dorrell, L. (2022) · Journal of Virus Eradication · doi:10.1016/j.jve.2022.100082 · Cited by 8
Next-generation sequencing and molecular therapy
Morton, C., Sarker, D., & Ross, P. (2023) · Clinical Medicine · doi:10.7861/clinmed.2022-0514 · Cited by 8
Regional chemotherapy for uveal melanoma liver metastases
Tao, Y.-X., Luo, J., Li, Y., & Wei, W. (2023) · International Journal of Ophthalmology · doi:10.18240/ijo.2023.02.18 · Cited by 8
Onken, M. D., Erdmann-Gilmore, P., Zhang, Q., Thapa, K., King, E. M., Kaltenbronn, K. M., Noda, S. E., Makepeace, C. M., Goldfarb, D., Babur, Ö., et al. (2023) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2023.100649 · Cited by 8
Walseng, E., Wang, B., Yang, C., Patel, P., Zhao, C., Zhang, H., Zhao, P., & Mazor, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1275304 · Cited by 8
Single locus HLA sequencing with the nanopore technology for HLA disease association diagnosis
Devriese, M., Rouquie, J., Silva, S. D., Benassaya, N., Maillard, L., Dewez, M., Caillat‐Zucman, S., Werner, G., & Taupin, J. (2024) · HLA · doi:10.1111/tan.15424 · Cited by 8
Hou, C., Wan, Q., Xiao, L., Xiao, Q., Zhang, M., & Yan, N. (2024) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.65.10.37 · Cited by 7
Cancer Therapy-Induced Encephalitis
Desbaillets, N., & Hottinger, A. F. (2024) · Cancers · doi:10.3390/cancers16213571 · Cited by 7
High-throughput screening for optimizing adoptive T cell therapies
Zhang, Y., Xu, Q., Gao, Z., Zhang, H., Xie, X., & Li, M. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00580-w · Cited by 8
Haus‐Cohen, M., & Reiter, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1486721 · Cited by 7
Bono, J. S. D., Williams, A., Melero, I., Jayaram, A., Hawley, J. E., de Spéville, B. D., Moreno, I., Castellano, D., Reig, Ò., Knapen, D. G., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3581 · Cited by 7
Approaches to overcome the current treatment plateau in immunotherapy
Giacomo, A. M. D., Canetta, R. M., Connolly, J., Leidner, R. S., Zheng, W., Kim, Y., Ibrahim, R. A., Lahn, M., Smith, M., Eggermont, A. M. M., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115605 · Cited by 7
Targeting the roots of myeloid malignancies with T cell receptors
Földvári, Z., Brennan, M. S., Titov, A., Jacobsen, S. E. W., & Olweus, J. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00857-0 · Cited by 8
Sato, T., Butler, M. O., Piperno-Neumann, S., Hassel, J. C., Nathan, P., Shoushtari, A. N., Rutkowski, P. L., Carvajal, R. D., Baurain, J., Schlaak, M. S., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-1513 · Cited by 7
Self-citationLim, T., Montazeri, K., Wehrenberg-Klee, E. P., Desîlets, A., Seedor, R. S., Orloff, M. M., Sato, T., Caplan, M., El-Ashmawy, M., Izar, B., et al. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf323 · Cited by 7
Self-citationOseni, S. O., Wang, Y., & Hwu, P. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.08.013 · Cited by 8
Beyond monospecificity: The modular revolution of bispecific immunotherapeutics
Fattahi, A. S., & Haghighi, E. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.105003 · Cited by 7
Immunotherapy for Solid Tumours: Current Clinical Landscape and Future Directions
van Diepen, A. E., Kucukcelebi, S., de Vos‐Geelen, J., & Kooreman, N. G. (2025) · European Surgical Research · doi:10.1159/000549862 · Cited by 7
Identification of targetable epigenetic vulnerabilities for uveal melanoma
Yenisehirli, G., Borges, S., Braun, S. S., Zuniga, A. N., Quintana, G. I., Kuznetsoff, J. N., Volonterio, R. L., Rodríguez, S., Adis, E. V., Lopez, S., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08295-4 · Cited by 7
Lapadula, D., Lam, B., Terai, M., Sugase, T., Tanaka, R., Farias, E., Kadamb, R., Lopez-Anton, M., Heine, C. C., Modasia, B., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0147 · Cited by 7
Targeting the cMET pathway to enhance immunotherapeutic approaches for mUM patients
Machiraju, D., & Hassel, J. C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1068029 · Cited by 7
Self-citationSah, V. R., Jespersen, H., Karlsson, J. W., Nilsson, L. M., Bergqvist, M., Johansson, I., Carneiro, A., Helgadóttir, H., Levin, M., Ullenhag, G. J., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0490 · Cited by 7
The Value of Microbes in Cancer Neoantigen Immunotherapy
Tian, J., & Ma, J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082138 · Cited by 8
Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma
Prieto, N. M. R., Turko, P., Zellweger, C., Nguyen‐Kim, T. D. L., Staeger, R., Bellini, E., Levesque, M. P., Dummer, R., & Ramelyte, E. (2023) · Melanoma Research · doi:10.1097/cmr.0000000000000952 · Cited by 8
Self-citationMechanism-Driven Design of Multispecific Antibodies for Targeted Disease Treatment
Fine, J., Meksiriporn, B., Tan, J., & Spangler, J. B. (2024) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-100522-102155 · Cited by 7
Updates in the Management of Uveal Melanoma
Barbi, M., Carvajal, R. D., & Devoe, C. (2024) · The Cancer Journal · doi:10.1097/ppo.0000000000000708 · Cited by 7
Self-citationMaurer, A. B., Clerici, G., Schaab, J. A., Cheng, P. F., Mihic‐Probst, D., Mader, C. E., Messerli, M., Huellner, M. W., Dummer, R., & Dimitriou, F. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01497-8 · Cited by 7
Self-citationAntibody-Based Therapies for Peripheral T-Cell Lymphoma
Shafagati, N., Paul, S., Rozati, S., & Sterling, C. H. (2024) · Cancers · doi:10.3390/cancers16203489 · Cited by 7
Ribeiro, A. R., Britton-Rivet, C., Collins, L. C., Carreira, R. J., Moureau, S., Benlahrech, A., Stanhope, S., Harper, S. J., Liddy, N., Mahon, T., et al. (2024) · Immunotherapy Advances · doi:10.1093/immadv/ltae008 · Cited by 7
Altan, M., Lopes, G. D. L., Jr., Hiltermann, T. J. N., Govindan, R., Villaruz, L. C., Calvo, E., Edelman, M. J., Furqan, M., Neal, J. W., Felip, E., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1591 · Cited by 7
Surveillance for Metastasis in Low-Risk Uveal Melanoma Patients
Delaney, A., Yeşiltaş, Y. S., Zabor, E. C., & Singh, A. D. (2025) · Ophthalmology · doi:10.1016/j.ophtha.2025.03.019 · Cited by 7
BAP1 Loss Affords Lipotoxicity Resistance in Uveal Melanoma
Cunanan, C. J., Amirfallah, A., Sanders, A., Gallant, K. C., Cavallo, M. R., Homer, E. M., Naggar, O. S. E., Farnan, J. K., Romano, G., Hope, J. L., et al. (2025) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.70021 · Cited by 7
Tebentafusp for the Treatment of Metastatic Uveal Melanoma
Schank, T. E., & Hassel, J. C. (2022) · Future Oncology · doi:10.2217/fon-2021-1260 · Cited by 7
Self-citationBispecific Antibodies Progression in Malignant Melanoma
Tang, J., Gong, Y.-L., & Ma, X.-L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.837889 · Cited by 6
Shalata, W., Attal, Z. G., Shhadi, R., Salman, A. A., Jama, A. A., Shalata, S., Halumi, K., & Yakobson, A. (2023) · Medicina · doi:10.3390/medicina59111946 · Cited by 7
Mitra, A., Lee, J. B., Steinbach, D., Hazra, A., & Krishna, R. (2023) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-023-09896-2 · Cited by 7
Nanomedicine-Based Treatments for Rare and Aggressive Ocular Cancers: Advances in Drug Delivery
Kapoor, D. U., Patel, G. K., & Prajapati, B. G. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01330-8 · Cited by 6
A Consolidated Review of Contemporary Targeted and Immunotherapeutic Options for Melanoma
Champion, P. J., Bluestein, J. R., Quinn, A. E., Bell, S. D., Kiley, J. H., Wakefield, M. R., & Fang, Y. (2025) · Biomedicines · doi:10.3390/biomedicines13061388 · Cited by 6
A Brief Overview of Uveal Melanoma Treatment Methods with a Focus on the Latest Advances
Wdowiak, K., Dolar-Szczasny, J., Ręjdak, R., Drab, A., & Maciocha, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14124058 · Cited by 6
Machiraju, D., Ziener, C. H., Clementi, E., García-Asencio, F., Hüllein, J., Richter, J., Lenoir, B., Wiecken, M., Hübschmann, D., Jäger, D., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03451-2 · Cited by 6
Self-citationVega-Rubín-de-Celis, S., Kristani, A., Kudla, M., Mergener, S., Corrochano-Ruiz, A., Larafa, S., Montero-Vergara, J., Ahle, L.-M., Will, R. D., Lever, M., et al. (2025) · Autophagy · doi:10.1080/15548627.2025.2535265 · Cited by 6
Evolution of bispecific and multispecific antibodies in cancer therapy
Fontana, E., Grochot, R. M., Kotecki, N., Doger, B., Nannini, S., & de Miguel, M. Á. F. (2026) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2026.101599 · Cited by 6
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy)
Ascierto, P. A., Agarwala, S. S., Blank, C. U., Caracò, C., Carvajal, R. D., Ernstoff, M. S., Ferrone, S., Fox, B. A., Gajewski, T. F., Garbe, C., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03592-4 · Cited by 6
Self-citationWallace, Z., Kopycinski, J. T., Yang, H., McCully, M. L., Eggeling, C., Chojnacki, J., & Dorrell, L. (2022) · Scientific Reports · doi:10.1038/s41598-022-23228-3 · Cited by 6
The making of multivalent gamma delta TCR anti-CD3 bispecific T cell engagers
van Diest, E., Nicolasen, M. J. T., Kramer, L., Zheng, J., Hernández-López, P., Beringer, D. X., & Kuball, J. H. E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1052090 · Cited by 6
The Cancer Genome Atlas for uveal melanoma is predictive of patient outcomes
Baş, Z., Grant-Kels, J. M., & Shields, C. L. (2023) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2023.10.005 · Cited by 6
Rodriguez, I., Norman, T. E., Guenther, J. S., Smart, K., Kwong, A., Berry, J. L., In, G. K., & Worswick, S. (2023) · Clinical and Experimental Dermatology · doi:10.1093/ced/llad387 · Cited by 6
Karlsson, J. W., Sah, V. R., Bagge, R. O., Kuznetsova, I., Iqba, M., Alsén, S., Stenqvist, S., Saxena, A., Ny, L., Nilsson, L. M., et al. (2023) · eLife · doi:10.7554/elife.91705 · Cited by 7
A replicating LCMV-based vaccine for the treatment of solid tumors
Purde, M.-T., Cupovic, J., Palmowski, Y., Makky, A., Schmidt, S., Rochwarger, A., Hartmann, F., Stemeseder, F., Lercher, A., Abdou, M.-T., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.11.026 · Cited by 6
Immunotherapy for mucosal melanoma
Du, Y., Bai, X. L., & Si, L. (2023) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000019 · Cited by 7
Tebentafusp as a Promising Drug for the Treatment of Uveal Melanoma
Balushi, K. A. A., Hadhrami, A. A., Balushi, H. A., Lawati, A. A., & Das, S. (2023) · Current Drug Targets · doi:10.2174/0113894501280380231214105255 · Cited by 6
Gonzalez, N. S., Marchese, P. V., Baraibar, I., Ros, J., Salvà, F., Rodrı́guez, M., Salvà, C., Vaghi, C., Alcaráz, A., García, A., et al. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2349287 · Cited by 6
Trogdon, M., Abbott, K. L., Arang, N., Lande, K., Kaur, N., Tong, M. M., Bakhoum, M. F., Gutkind, J. S., & Stites, E. C. (2024) · npj Systems Biology and Applications · doi:10.1038/s41540-024-00400-1 · Cited by 7
TCR-like bispecific antibodies toward eliminating infected hepatocytes in HBV mouse models
Shi, Y., Wang, Z., Xu, J., Niu, W., Wu, Y., Huiyu, G., Shi, J., Li, Z., Fu, B., Hong, Y., et al. (2024) · Emerging Microbes & Infections · doi:10.1080/22221751.2024.2387448 · Cited by 7
Wiens, L., Grözinger, G., Dittmann, H., Thiel, K., Leiter, U., Amaral, T. M. S., Nanz, L., Flatz, L., & Forschner, A. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241273020 · Cited by 6
Kefas, J., & Flynn, M. (2024) · Cancer Drug Resistance · doi:10.20517/cdr.2024.67 · Cited by 6
Liu, L., Yao, W., Wang, M., Wang, B., Kong, F., Fan, Z., & Fan, G. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.10.004 · Cited by 6
Amaral, T. M. S., Nanz, L., Serna-Higuita, L. M., Ascierto, P. A., Berking, C., Muñoz‐Couselo, E., Donia, M., Dummer, R., Gutzmer, R., Haushild, A., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115160 · Cited by 6
Self-citationCiernik, A., Ciernik, L., Bonczkowitz, P., Morak, M., Heinzerling, L. M., Bennaceur, Y., Lawless, A. R., Sullivan, R. J., Kött, J., Gebhardt, C., et al. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf173 · Cited by 6
Self-citationManagement of metastatic uveal melanoma: French expert consensus guidelines
Rodrigues, M. J., Servois, V., Mariani, P., Pracht, M., Dutriaux, C., Grillet, F., Ryckwaert, T., Ducoulombier, A., Neidhardt, E., & Piperno-Neumann, S. (2025) · Bulletin du Cancer · doi:10.1016/j.bulcan.2025.05.011 · Cited by 6
Self-citationWang, H., Zhao, S., Liu, Y., Sun, F., Huang, X., & Wu, T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.898047 · Cited by 6
Ramtohul, T., Abdul-Baki, M., Rodrigues, M. J., Cassoux, N., Gardrat, S., Raïs, K. A., Pierron, G., Bouhadiba, T., Servois, V., & Mariani, P. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-12368-5 · Cited by 6
Glinkina, K., Némati, F., Teunisse, A. F. A. S., Gelmi, M. C., Etienne, V., Kuipers, M. J., Alsafadi, S., Jager, M. J., Decaudin, D., & Jochemsen, A. G. (2022) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.63.13.14 · Cited by 6
Identification of a prognostic six-immune-gene signature and a nomogram model for uveal melanoma
Yang, B., Fan, Y., Liang, R., Wu, Y.-L. L. C., & Gu, A. (2023) · BMC Ophthalmology · doi:10.1186/s12886-022-02723-1 · Cited by 6
Martel, A., Gastaud, L., Bonnetaud, C., Nahon‐Estève, S., Washetine, K., Bordone, O., Salah, M., Tanga, V., Fayada, J., Lespinet‐Fabre, V., et al. (2023) · Cancers · doi:10.3390/cancers15082372 · Cited by 6
Self-citationTebentafusp: The First FDA-approved Monoclonal Antibody for Cancer Treatment in 2022
Kozani, P. S., Kozani, P. S., & Sheikhi, A. (2022) · Trends in Medical Sciences · doi:10.5812/tms.123546 · Cited by 6
Combined Mcl-1 and YAP1/TAZ inhibition for treatment of metastatic uveal melanoma
Glinkina, K., Teunisse, A. F. A. S., Gelmi, M. C., de Vries, J., Jager, M. J., & Jochemsen, A. G. (2023) · Melanoma Research · doi:10.1097/cmr.0000000000000911 · Cited by 6
A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics
Meyer, M. E., Mahr, A., Brewer, J. E., Daniel, V., Dell’Aringa, J., Goldstone, T., Hersey, S., Johnston, I., Larson, P., Loveridge, M., et al. (2023) · Nature Reviews Drug Discovery · doi:10.1038/d41573-023-00189-4 · Cited by 6
Current Therapies and Potential Strategies for Uveal Melanoma
Scoles, S., Ganesh, S., & Yamada, K. H. (2025) · Drugs and Drug Candidates · doi:10.3390/ddc4020014 · Cited by 5
Sachpekidis, C., Machiraju, D., Strauss, D. S., Pan, L., Kopp‐Schneider, A., Edenbrandt, L., Dimitrakopoulou‐Strauss, A., & Hassel, J. C. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07504-8 · Cited by 5
Self-citationRenac, V., Moalic, V., Dautin, G., Chérel, M., Mercier, B., Walencik, A., Cohen, J. H. M., Farce, F., Proust, B., Kaveri, R., et al. (2025) · HLA · doi:10.1111/tan.70442 · Cited by 5
Cunanan, C. J., Sanders, A. B., Gallant, K. C., Seedor, R. S., & Hartsough, E. J. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10298-8 · Cited by 5
Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy
Kang, X., Zhao, Y., Ling, H., & Huang, X. (2025) · Antibody Therapeutics · doi:10.1093/abt/tbaf026 · Cited by 5
Zaghla, B. K. Q., Safyürek, Z., Gröger, D., Mecklenbräuker, S., Lingstädt, N.-S., Popp, O., Spengler, J., Haji, M., Montesion, M., Albacker, L. A., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013271 · Cited by 5
Targeting peptide–HLA complexes for precision immunotherapy
Bi, J., Jiang, L., Zhao, J., Zhuang, X., & Pan, L. (2026) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.11.007 · Cited by 5
Cell Therapies and Bispecific Engagers: Redefining Strategies against Checkpoint Resistance
Laubli, H. P., König, D., Donia, M., Binder, M., & Zippelius, A. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3694 · Cited by 5
Zeyaullah, M., AlShahrani, A. M., Khan, M. S., Ahmad, M. F., Altijani, A. A. G., Mohamed, A. O. A., Hummad, H., Mohieldin, A., & Ahmad, S. R. (2026) · Cancers · doi:10.3390/cancers18071088 · Cited by 5
Landscape of T-cell engagers in solid tumors
Garcia-Lorenzo, E., Dorta, M., Doger, B., Pedregal, M., & Moreno, V. (2026) · The Oncologist · doi:10.1093/oncolo/oyag129 · Cited by 5
Generalizable design parameters for soluble T cell receptor-based T cell engagers
Froning, K., Sereno, A., Huang, F., & Demarest, S. J. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004281 · Cited by 6
New immunotherapy approaches as the most effective treatment for uveal melanoma
Eteghadi, A., Ebrahimi, M., & Keshel, S. H. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104260 · Cited by 5
Mariani, P., Pierron, G., Raïs, K. A., Bouhadiba, T., Rodrigues, M. J., Malaise, D., Rouïc, L. L.-L., Barnhill, R. L., Stern, M., Servois, V., et al. (2024) · Cancers · doi:10.3390/cancers16193407 · Cited by 5
Ramelyte, E., Kött, J., Lawless, A. R., Ciernik, A., Heidrich, I., Zellweger, C., Montazeri, K., Mangana, J., Smit, D. J., Freiberger, S. N., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-2274 · Cited by 5
Self-citationShared PRAME epitopes are T-cell targets in NUT carcinoma
Jensen, J. L., Peterson, S. K., Sambade, M. J., Alley, J., Yu, S., Kinjo, T., Bennett, S., Vensko, S. P., II, Shabrang, M., DeBetta, J. D., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013539 · Cited by 5
Targeted Therapy for Melanomas Without BRAF V600 Mutation
Choi, J. S., & Chandra, S. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01306-z · Cited by 5
Top advances of the year: Melanoma
Augustin, R. C., & Luke, J. J. (2023) · Cancer · doi:10.1002/cncr.34590 · Cited by 5
Schossig, P., Coskun, E., Arsenić, R., Horst, D. A., Sehouli, J., Bergmann, E. C., Andresen, N., Sigler, C., Busse, A., Keller, U. B., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032292 · Cited by 5
Self-citationAdjuvant melatonin for uveal melanoma (AMUM): protocol for a randomized open-label phase III study
Omar, R. K., Hagström, A., & Stålhammar, G. (2023) · Trials · doi:10.1186/s13063-023-07245-9 · Cited by 5
Orozco, C. A., Mejía‐García, A., Ramírez, M., González, J., Castro‐Vega, L. J., Kreider, R. B., Serrano, S., Cómbita, A. L., & Bonilla, D. A. (2023) · Biomolecules · doi:10.3390/biom13071148 · Cited by 5
Targeted Approaches to Treatment of Pleural Mesothelioma: A Review
Dagogo‐Jack, I. (2023) · JCO Precision Oncology · doi:10.1200/po.23.00344 · Cited by 5
Song, L., Yang, Y., & Tian, X. (2024) · Cancer Drug Resistance · doi:10.20517/cdr.2023.150 · Cited by 5
Improving CD3 bispecific antibody therapy in solid tumors using combination strategies
Lloyd, K. A., Middelburg, J., Ovcinnikovs, V., Pencheva, N., Kemper, K., & van Hall, T. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1548446 · Cited by 5
Uveal melanoma metastatic at initial diagnosis: a case series
Steckler, A. M., Francis, J. H., Shoushtari, A. N., Abramson, D. H., & Barker, C. A. (2022) · Melanoma Research · doi:10.1097/cmr.0000000000000807 · Cited by 5
Self-citationRola, A. C., Kalirai, H., Taktak, A. F. G., Eleuteri, A., Krishna, Y., Hussain, R. N., Heimann, H., & Coupland, S. E. (2022) · Cancers · doi:10.3390/cancers14092187 · Cited by 5
Rutkowski, P. L., Romanowska‐Dixon, B., Markiewicz, A., Zieniewicz, K., Kozak, K., Rogala, P., Świtaj, T., & Dudzisz‐Śledź, M. (2022) · Nowotwory Journal of Oncology · doi:10.5603/njo.2022.0054 · Cited by 5
Self-citationTong, T. M. L., Bastiaannet, E., Speetjens, F. M., Blank, C. U., Luyten, G. P. M., Jager, M. J., Marinkovic, M., Vu, T. H. K., Rasch, C. R. N., Creutzberg, C. L., et al. (2023) · Cancers · doi:10.3390/cancers15225419 · Cited by 5
Yu, I. S., Wee, K., Williamson, L., Titmuss, E., An, J., Naderi-Azad, S., Metcalf, C., Yip, S. S. F., Horst, B. A. J., Jones, S. J. M., et al. (2022) · Melanoma Research · doi:10.1097/cmr.0000000000000810 · Cited by 5
A Marathon Not a Sprint: Improving Outcomes for Patients With Metastatic Melanoma in 2022 and Beyond
Kennedy, L. B., & Salama, A. K. S. (2022) · JCO Oncology Practice · doi:10.1200/op.22.00012 · Cited by 5
Self-citation
Metadata
- Authors
- Nathan, P., Hassel, J. C., Rutkowski, P., Baurain, J.-F., Butler, M. O., Schlaak, M., Sullivan, R. J., Ochsenreither, S., Dummer, R., Kirkwood, J. M., Joshua, A. M., Sacco, J. J., Shoushtari, A. N., Orloff, M., Piulats, J. M., Milhem, M., Salama, A. K. S., Curti, B., Demidov, L., Gastaud, L., Mauch, C., Yushak, M., Carvajal, R. D., Hamid, O., Abdullah, S. E., Holland, C., Goodall, H., & Piperno-Neumann, S.
- Affiliations
- University of Liverpool (GB)
- From Mount Vernon Cancer Centre, Northwood (P.N.), the Clatterbridge Cancer Centre NHS Foundation Trust, Wirral (J.J.S.), the University of Liverpool, Liverpool (J.J.S.), and Immunocore, Abingdon (S.E.A., C.H., H.G.) — all in the United Kingdom; the Department of Dermatology and the National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg (J.C.H.), the Department of Dermatology and Allergy, University Hospital, Ludwig Maximilian University of Munich, Munich (M.S.), the Department of Hematology and Oncology, Charité–Comprehensive Cancer Center (S.O.), Berlin, and the Department of Dermatology and the Center for Integrated Oncology, University Hospital Cologne, Cologne (C.M.) — all in Germany; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland (P.R.); Institut Roi Albert II des Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels (J.-F.B.); Princess Margaret Cancer Centre, Toronto (M.O.B.); Massachusetts General Hospital Cancer Ce...
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Nathan, Paul
- Hassel, Jessica C.
- Rutkowski, Piotr
- Butler, Marcus O.
- Schlaak, Max
- Sullivan, Ryan J.
- Ochsenreither, Sebastian
- Dummer, Reinhard
- Kirkwood, John M.
- Joshua, Anthony M.
- Sacco, Joseph J.
- Shoushtari, Alexander N.
- Orloff, Marlana
- Piulats, Josep M.
- Milhem, Mohammed
- Salama, April K.S.
- Curti, Brendan
- Mauch, Cornelia
- Yushak, Melinda
- Carvajal, Richard D.
- Hamid, Omid
- Abdullah, Shaad E.
- Piperno-Neumann, Sophie
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-09-23
- Volume
- 385
- Issue
- 13
- Pages
- 1196-1206
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3200574709
- Cited by
- 924
- References
- 28
- Citations by year
- 2026: 158 · 2025: 181 · 2024: 216 · 2023: 205 · 2022: 148 · 2021: 15
- FWCI
- 131.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- metastatic uveal melanoma, bispecific T-cell engagers, anti-CD3 antibody, pembrolizumab, ipilimumab, dacarbazine, overall survival, progression-free survival, HLA-A*0201, cytokine release syndrome, treatment-related adverse events, treatment-naive patients
- MeSH terms
- Ipilimumab, Cytokine Release Syndrome, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Dacarbazine, Exanthema, Female, Humans, Male, Melanoma, Middle Aged, Recombinant Fusion Proteins, Uveal Neoplasms, Survival Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
